What's in Baxis Pharmaceuticals, Inc.'s pipeline?

Baxis Pharmaceuticals, Inc. has 1 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Baxis Pharmaceuticals, Inc.'s portfolio?

Top competitors by shared drug class: LEO Pharma.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/baxis-pharmaceuticals-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

Baxis Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Baxis Pharmaceuticals, Inc. pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Fusidic Acid 1%	Fusidic Acid 1%	phase 3	Steroid antibiotic	Bacterial elongation factor G (EF-G)	Infectious Disease

Therapeutic area mix

Infectious Disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

LEO Pharma · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Baxis Pharmaceuticals, Inc.:

Cite this brief

Drug Landscape (2026). Baxis Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/baxis-pharmaceuticals-inc. Accessed 2026-06-10.